Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR

Volker Heinemann(LMU Klinikum), Andreas Jung(Ludwig-Maximilians-Universität München), Thomas Kirchner(Friedrich-Alexander-Universität Erlangen-Nürnberg), Sebastian Stintzing(Humboldt-Universität zu Berlin), Stefan Boeck(German Cancer Research Center)

Cancer Treatment Reviews

December 31, 2008

10.1016/j.ctrv.2008.11.005

Cited by 205

Related Papers

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

|The Lancet|2019|2.6k

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

|The Lancet Oncology|2014|1.7k

Prognostic and Predictive Relevance of Primary Tumor Location in Patients With <i>RAS </i>Wild-Type Metastatic Colorectal Cancer

|JAMA Oncology|2016|722

β-Catenin Regulates the Expression of the Matrix Metalloproteinase-7 in Human Colorectal Cancer

|American Journal Of Pathology|1999|663

The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials

|European Journal of Cancer|2016|533